drugset / Trial / NCT02575794
Terameprocol in Treating Patients With Recurrent High Grade Glioma
Phase 1
Completed
20 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Erimos Pharmaceuticals · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of terameprocol in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as terameprocol, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2018-05-03
- Primary completion
- 2023-09-30
- Completion
- 2023-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Terameprocol | Small molecule | 1200 mg | Oral |
| Subject | Terameprocol | Small molecule | 2400 mg | Oral |
| Subject | Terameprocol | Small molecule | 3600 mg | Oral |
| Subject | Terameprocol | Small molecule | 6000 mg | Oral |